Indication
Disseminated sporotrichosis
Disseminated sporotrichosis is a rare, severe, systemic fungal infection caused by dimorphic fungi of the *Sporothrix* species complex (most notably *Sporothrix schenckii* and *Sporothrix brasiliensis*). Read more about Disseminated sporotrichosis
3 drugs 3 manufacturers
Drugs that treat it
Common Disseminated sporotrichosis therapies.
ABELCET (amphotericin B lipid complex)
ABELCET (amphotericin B lipid complex)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonDisseminated sporotrichosis is a rare, severe, systemic fungal infection caused by dimorphic fungi of the *Sporothrix* species complex (most notably *Sporothrix schenckii* and *Sporothrix brasiliensis*).
It arises when the fungus spreads hematogenously beyond the initial cutaneous inoculation or pulmonary site, primarily affecting severely immunocompromised hosts, such as individuals with advanced HIV infection, hematologic malignancies, or immunosuppressive therapy.
Clinically, the disease is characterized by widespread, ulcerating cutaneous or subcutaneous lesions alongside multi-organ seeding, which commonly involves the osteoarticular system, lungs, eyes, and central nervous system, leading to destructive tenosynovitis, osteomyelitis, or chronic fungal meningitis.
- nih.gov
Disseminated sporotrichosis is a rare, severe, systemic fungal infection caused by dimorphic fungi of the *Sporothrix* species complex (most notably *Sporothrix schenckii* and *Sporothrix brasiliensis*) It arises when the fungus spreads hematogenously beyond the initial cutaneous inoculation or pulmonary site, primarily affecting severely immunocompromised hosts, such as individuals with advanced HIV infection, hematologic malignancies, or immunosuppressive therapy
- nih.gov
Disseminated sporotrichosis is a rare, severe, systemic fungal infection caused by dimorphic fungi of the *Sporothrix* species complex (most notably *Sporothrix schenckii* and *Sporothrix brasiliensis*) It arises when the fungus spreads hematogenously beyond the initial cutaneous inoculation or pulmonary site, primarily affecting severely immunocompromised hosts, such as individuals with advanced HIV infection, hematologic malignancies, or immunosuppressive therapy Clinically, the disease is cha...
- cdc.gov
It arises when the fungus spreads hematogenously beyond the initial cutaneous inoculation or pulmonary site, primarily affecting severely immunocompromised hosts, such as individuals with advanced HIV infection, hematologic malignancies, or immunosuppressive therapy Clinically, the disease is characterized by widespread, ulcerating cutaneous or subcutaneous lesions alongside multi-organ seeding, which commonly involves the osteoarticular system, lungs, eyes, and central nervous system, leading t...
- nih.gov
It arises when the fungus spreads hematogenously beyond the initial cutaneous inoculation or pulmonary site, primarily affecting severely immunocompromised hosts, such as individuals with advanced HIV infection, hematologic malignancies, or immunosuppressive therapy
- cdc.gov
Clinically, the disease is characterized by widespread, ulcerating cutaneous or subcutaneous lesions alongside multi-organ seeding, which commonly involves the osteoarticular system, lungs, eyes, and central nervous system, leading to destructive tenosynovitis, osteomyelitis, or chronic fungal meningitis
Personalize your experience
Follow Disseminated sporotrichosis and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.